Engineering Nanoplatforms for Alzheimer's Disease Detection via Biomolecular Corona Proteomic and Lipidomic Profiling
Advanced Healthcare Materials · 2026-08 · 15 (31)
DOI: 10.1002/adhm.71441 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 11.07.2026. Verfasst von Antonietta Greco und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Surgery, Nanomedicine Center Nanomib, University of Milano Bicocca, Vedano al Lambro, MB, Italy. Hauptthemen laut MEDLINE: Alzheimer Disease, Proteomics, Lipidomics, Nanoparticles. Die Arbeit nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Next Generation EU PRIN 2022, University of Milan Bicocca.
Themen: Demenz
Abstract (Originalsprache)
The escalating global prevalence of Alzheimer's disease (AD) requires the development of sensitive, non‐invasive diagnostic strategies capable of detecting pathological changes previous the clinical onset. By exploiting the spontaneous formation of the biomolecular corona (BC) around nanoparticles (NPs), it's possible to capture a rich, disease‐specific fingerprint from the plasma that reflects systemic alterations often invisible to traditional diagnostic assays. In the present study, we demonstrate the efficacy of an innovative nanotechnological platform utilizing a synergistic dual‐silica NPs system (comprising amino‐ and sulfonate‐functionalized surfaces) integrated with proteomic and lipidomic profiling of the NP‐associated BC. Our results revealed a significant enrichment of ribosomal machinery in the BC of AD patients, contrasted by a simultaneous decrease of glycolytic enzymes and mitochondrial respiratory components. This metabolic impairment is further corroborated by the lipidomic profile, which shows a reduction in short‐chain acyl‐carnitines (C2, C3, C5) and essential membrane phospholipids. Additionally, the observed loss of structural proteins, such as Cofilin‐1 and Vinculin, contributes to a comprehensive molecular fingerprint unique to the AD phenotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine and Surgery, Nanomedicine Center Nanomib, University of Milano Bicocca, Vedano al Lambro, MB, Italy.
- Department of Chemical Sciences, University of Padova, Padova, Italy.
- Analytical Chemistry Lab, Istituto Italiano di Tecnologia, Genoa, Italy.
- Department of Pharmacy, University of Naples "Federico II", Naples, Italy.
- Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania, USA.
- Bioelectronics Task Force at University of Naples Federico II, Naples, Italy.
ORCID-Profile: Andrea Armirotti, Stefano Cinti, Marco Frasconi, Claudia Corbo
Förderung
- Next Generation EU PRIN 2022
- University of Milan Bicocca
Zitieren
APA
Greco, A., Baretta, R., Fonzo, A. D., Armirotti, A., Cinti, S., Mirasoli, M., Frasconi, M., & Corbo, C. (2026). Engineering Nanoplatforms for Alzheimer's Disease Detection via Biomolecular Corona Proteomic and Lipidomic Profiling. Advanced Healthcare Materials, 15(31). https://doi.org/10.1002/adhm.71441
Vancouver
Greco A, Baretta R, Fonzo AD, Armirotti A, Cinti S, Mirasoli M, et al. Engineering Nanoplatforms for Alzheimer's Disease Detection via Biomolecular Corona Proteomic and Lipidomic Profiling. Advanced Healthcare Materials. 2026;15(31). doi:10.1002/adhm.71441
BibTeX
@article{Greco2026,
author = {Greco, Antonietta and Baretta, Roberto and Fonzo, Andrea Di and Armirotti, Andrea and Cinti, Stefano and Mirasoli, Mara and Frasconi, Marco and Corbo, Claudia},
title = {Engineering Nanoplatforms for Alzheimer's Disease Detection via Biomolecular Corona Proteomic and Lipidomic Profiling},
journal = {Advanced Healthcare Materials},
year = {2026},
volume = {15},
number = {31},
doi = {10.1002/adhm.71441}
}
EUVIMED